| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | selected |
| Process | STA Standard |
| ID number | 6480 |
Provisional Schedule
| Committee meeting: 1 | 02 July 2025 |
| Expected publication | 11 September 2025 |
Project Team
| Project lead | Vonda Murray |
Email enquiries
- If you have any queries please email tateam3@nice.org.uk
Stakeholders
| Companies sponsors | Sanofi (dupilumab) |
| Others | Department of Health and Social Care |
| Health Technology Wales (HTW) | |
| NHS England | |
| Patient carer groups | Fifth Sense |
| Sinus UK | |
| Professional groups | Association of Respiratory Nurse Specialists |
| Royal College of Physicians | |
| Comparator companies | None |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| NHS Wales Joint Commissioning Committee | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Relevant research groups | None |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 November 2024 | Invitation to participate |
| 19 November 2024 | In progress |
| 22 October 2024 - 05 November 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on how we select topics for development, please see our page about prioritising our guidance topics